Shield Therapeutics strengthens team with key Board and senior management appointments

9 May 2013

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces two new appointments with Dr Lynn Drummond joining the Board as a Non-Executive Director and Dr Julian Howell joining the senior management team as Group Medical Director and VP of Drug Development.

Dr Drummond has a strong track record within the life sciences sector, bringing over 25 years of management and advisory experience. Dr Drummond spent 16 years at Rothschild in London, most recently as a Managing Director within the investment banking division, with a particular focus on transactions within the healthcare sector. Prior to this she worked in the Cabinet Office of the UK Government as Private Secretary to the Chief Scientific Advisor and spent the early part of her career as a research scientist. Dr Drummond is currently Non-Executive Chairman of infirst Healthcare and a Non-Executive Director of Consort Medical plc and Allocate Software plc. She holds a PhD in Biochemistry from the University of London, and is also a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Edinburgh.

Dr Howell is a pharmaceutical physician with more than 14 years of medical affairs and pharmaceutical development experience across a broad range of therapeutic areas. He joins Shield following six years at ProStrakan where he led the clinical development and drug safety group, achieving six product approvals in the US and Europe. Following a research post at Glasgow University, Julian joined the industry first at SmithKline Beecham and then at Roche, before moving to smaller organisations. Prior to that, he gained medical and surgical qualifications during six years in the NHS and an MBA from Cranfield University.

Commenting on the appointments Carl Sterritt, Founder and Chief Executive Officer of Shield Therapeutics, said:

“I am delighted to welcome Lynn to the Board of Shield Therapeutics and Julian to the senior management team. We are approaching data readout from our pivotal studies of ST10 and expect the upcoming period to be of critical importance to the Company, so a key consideration in these appointments was the desire to add a combination of significant industry and transactional experience to the team. I am pleased that we have achieved that goal and I look forward to Shield Therapeutics benefiting from both Lynn’s and Julian’s valuable contributions to our activities.

Back to news